OncoMatch/Bladder Cancer (Urothelial)/PD-L1 (CD274)
Bladder Cancer (Urothelial)PD-L1 (CD274) Clinical Trials
Enfortumab vedotin plus pembrolizumab is now the FDA-approved first-line standard for advanced urothelial carcinoma regardless of PD-L1 status (EV-302/KEYNOTE-869, approved December 2023). For cisplatin-ineligible patients not receiving EV+pembro, PD-L1 expression (IC score ≥1% by SP142) guided atezolizumab eligibility; pembrolizumab monotherapy is approved in second-line disease regardless of PD-L1. Trials investigate novel checkpoint combinations, neoadjuvant IO strategies, and biomarker-refined patient selection.
Top recruiting PD-L1 (CD274) Bladder Cancer (Urothelial) trials
Ranked by phase and US site count. See all 6 trials matched to your profile →
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Fujian Medical University Union Hospital
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Cancer Institute (NCI)
Browse other molecular targets with active Bladder Cancer (Urothelial) trials.